± HEALTH Objective To evaluate the accuracy, completeness, clarity, source transparency, and readability of leading AI…+ HEALTH Background Early prediction of in-hospital mortality in critically ill patients can aid clinicians in optimiz…+ HEALTH Hypertension is a major risk factor for cardiovascular diseases, with changes in gut microbiota composition a…+ SCIENCE Fire ants (Solenopsis spp. Westwood) pose a major ecological and economic threat, mainly due to the invasive…± HEALTH Objectives The current study aimed to quantify the diagnostic accuracy of commonly utilized chatbots includin…+ HEALTH Objective Despite elevated risk for epilepsy following traumatic brain injury (TBI), there are limited tools…± HEALTH Timely and accurate diagnosis of ST-elevation myocardial infarction (STEMI) is critical in military operation…+ HEALTH Colorectal cancer (CRC) exhibits substantial metabolic heterogeneity. This study developed a robust prognosti…
TruaceTracing the truth around AIWednesday, August 5, 2026
Subscribe
TRV-2026-0602Certified recordPeer-reviewed

Educational Artificial Intelligence Software to Support Assessment of Atopic Dermatitis Severity

Accurate assessment of the severity of atopic dermatitis is crucial for guiding treatment. However, the Eczema Area and Severity Index (EASI), a widely used clinical assessment tool, relies on subjective visual scoring, which can lead to inter-rater variability. This study aimed to evaluate the performance of convolutional neural network-based artificial intelligence software in assessing atopic dermatitis severity from uncropped, unmasked skin images acquired under uncontrolled conditions. In this prospective,…

Health · G Space — documented gain · certified 2026-07-31 · v1 · article view · machine-readable

Current reading — gain

ConvNeXt-based AI trained on 3676 smartphone images from 1016 patients achieved AUCs of 0.825-0.860 for EASI component scores >=2 and >0.900 for score 3, supporting use as an educational tool to standardize EASI scoring.

What this doesn’t fix

Software is positioned as educational support only and not validated for direct clinical decision-making at this stage, with performance varying by sign and lowest for papulation/edema.

Evidence

Reader signal

How should this claim be treated?

Cite this record

Truvace Impact Record TRV-2026-0602, v1: “Educational Artificial Intelligence Software to Support Assessment of Atopic Dermatitis Severity.” Truvace, 2026-07-31. /record/TRV-2026-0602 (accessed at citation time). sha256 dadf2990f8cfbc33…

Calibration history

Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.

  1. Certifiedv1dadf2990f8cf…

    Certified into the record

Verify this record
How to verify without trusting this page

Fetch the canonical text of any version from /api/record/TRV-2026-0602 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.